A clinical study of 24 patients treated with pembrolizumab for platinum-sensitive recurrent metastatic squamous cell carcinoma of the head and neck-Reference-Cited by-同舟云学术

A clinical study of 24 patients treated with pembrolizumab for platinum-sensitive recurrent metastatic squamous cell carcinoma of the head and neck

Published:2024 Issue:3 Volume:33 Page:301-309
ISSN:1349-581X
Container-title:JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
language:en
Short-container-title:J Jpn Soc Head Neck Surg

Author:

Higashi Arisa¹,Wakasugi Tetsuro¹,Hasegawa Shoichi¹,Takahashi Azusa¹,Takeuchi Shoko¹,Ohkubo Jun-Ichi¹

Affiliation:

1. University of Occupational and Environmental Health Japan, Department of Otorhinolaryngology-Head and Neck Surgery

Publisher

Japan Society for Head and Neck Surgery

Link

https://www.jstage.jst.go.jp/article/jjshns/33/3/33_33.301/_pdf

Reference13 articles.

1. 1） Burtness B, Harrington KJ, Greil R, et al: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck （KEYNOTE-048）: a randomised, open-label, phase 3 study. Lancet 394：1915-1928, 2019.

2. 2）日本頭頸部癌学会編：頭頸部癌診療ガイドライン2022，195-199，金原出版株式会社，東京，2022．

3. 3） Schwartz LH, Litière S, de Vries E, et al: RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancers 62：132-137, 2016.

4. 4） Burtness B, Rischin D, Greil R, et al: Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score. J Clin Oncol 40：2321-2332, 2022.

5. 5） Harrington KJ, Burtness B, Greil R, et al: Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase Ⅲ KEYNOTE-048 study. J Clin Oncol 41：790-802, 2023.